Reported Sunday, Genentech’s Divarasib Lowers Death Risk 44% In Phase III Krascendo 1 With Fewer TRAE Discontinuations (4.8% Versus 11.7%) Than Sotorasib Or Adagrasib In Previously Treated KRAS G12C NSCLC

Benzinga
Open on Benzinga